Jacobs Levy Equity Management’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.05M | Buy |
290,460
+172,293
| +146% | +$620K | ﹤0.01% | 748 |
|
|
2025
Q1 | $353K | Sell |
118,167
-272,732
| -70% | -$815K | ﹤0.01% | 961 |
|
|
2024
Q4 | $1.31M | Sell |
390,899
-118,572
| -23% | -$397K | ﹤0.01% | 676 |
|
|
2024
Q3 | $1.71M | Sell |
509,471
-55,427
| -10% | -$186K | 0.01% | 635 |
|
|
2024
Q2 | $1.87M | Sell |
564,898
-108,086
| -16% | -$358K | 0.01% | 613 |
|
|
2024
Q1 | $2.72M | Buy |
672,984
+122,447
| +22% | +$495K | 0.01% | 548 |
|
|
2023
Q4 | $1.68M | Sell |
550,537
-2,840
| -0.5% | -$8.66K | 0.01% | 632 |
|
|
2023
Q3 | $1.66M | Sell |
553,377
-11,395
| -2% | -$34.2K | 0.01% | 594 |
|
|
2023
Q2 | $2.11M | Sell |
564,772
-67,458
| -11% | -$252K | 0.01% | 554 |
|
|
2023
Q1 | $2.12M | Buy |
632,230
+133,172
| +27% | +$446K | 0.01% | 564 |
|
|
2022
Q4 | $2.4M | Buy |
499,058
+118,541
| +31% | +$570K | 0.02% | 518 |
|
|
2022
Q3 | $2.17M | Sell |
380,517
-51,921
| -12% | -$295K | 0.02% | 541 |
|
|
2022
Q2 | $3.07M | Buy |
432,438
+278,833
| +182% | +$1.98M | 0.02% | 511 |
|
|
2022
Q1 | $1.11M | Buy |
+153,605
| New | +$1.11M | 0.01% | 739 |
|